Figure 6.
Gene-set enrichment analysis with the significant differentially expressed proteins after 6- month treatment with denosumab. Blue bars to the right are showing upregulating effects to the specific pathway. Light blue is not significant (FDR > 0.05), whereas dark blue is significant (FDR < 0.05).